Role of Lutetium Radioligand Therapy in Prostate Cancer.

Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive ß-emitter 177Lu with Vipivotide Tetraxetan, a prostate-specific membrane antigen (PSMA)-binding ligand. Several studies have been conducted, and the therapy is not without adverse effects (e.g., xerostomia, nausea, and fatigue); however, few events are reported as severe. The available evidence supports the use of 177Lu-PSMA in selected metastatic castration-resistant prostate cancer patients, and the treatment is considered a standard of care in several clinical scenarios. Emerging research shows promising results in the setting of hormone-sensitive prostate cancer; however, evidence from high-quality controlled trials is still missing. In this review, we discuss the available evidence for the application of 177Lu-PSMA in the management of PCa patients.

The Influence of Anti-Diabetic Drugs on Prostate Cancer.

The incidences of prostate cancer (PC) and diabetes are increasing, with a sustained trend. The occurrence of PC and type 2 diabetes mellitus (T2DM) is growing with aging. The correlation between PC occurrence and diabetes is noteworthy, as T2DM is correlated with a reduced risk of incidence of prostate cancer. Despite this reduction, diabetes mellitus increases the mortality in many cancer types, including prostate cancer. The treatment of T2DM is based on lifestyle changes and pharmacological management. Current available drugs, except insulin, are aimed at increasing insulin secretion (sulfonylureas, incretin drugs), improving insulin sensitivity (biguanides, thiazolidinediones), or increasing urinary glucose excretion (gliflozin). Comorbidities should be taken into consideration during the treatment of T2DM. This review describes currently known information about the mechanism and impact of commonly used antidiabetic drugs on the incidence and progression of PC. Outcomes of pre-clinical studies are briefly presented and their correlations with available clinical trials have also been observed. Available reports and meta-analyses demonstrate that most anti-diabetic drugs do not increase the risk during the treatment of patients with PC. However, some reports show a potential advantage of treatment of T2DM with specific drugs. Based on clinical reports, use of metformin should be considered as a therapeutic option. Moreover, anticancer properties of metformin were augmented while combined with GLP-1 analogs.

Roles of microRNAs in abdominal aortic aneurysm pathogenesis and the possibility of their use as biomarkers.

Abdominal aortic aneurysm (AAA) is a dangerous condition involving pathological dilation of the aortic wall. Due to the asymptomatic course of this disease and the dangerous consequences of its rupture, it is important to identify its specific bio-markers expressed as early as possible. Different expression profiles of microRNAs (miRNAs) were detected in patients diagnosed with AAA. MicroRNAs are small non-coding RNA molecules that regulate the expression of other genes at the translation stage. miRNAs affecting translation can lead to abnormal remodeling of extracellular matrix, inhibition of the cell cycle, cell aging or intensified inflammation. This review summarizes current knowledge about the role of microRNAs in the context of formation and development of abdominal aorta aneurysm and the possibility of using some miRNAs as bio-markers, and also provides basic information about miRNAs and aneurysms.